Auxilium Pharmaceuticals (NASDAQ:AUXL) traded today at a new 52-week low of $16.88. So far today approximately 272,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares.
Auxilium Pharmaceuticals Inc. develops and commercializes pharmaceutical products that target urologic and sexual health disorders. The company's marketed product ,TESTIM, is a proprietary, topical 1% testosterone gel indicated for the treatment of hypogonadism.
There is potential upside of 46.0% for shares of Auxilium Pharmaceuticals based on a current price of $16.88 and an average consensus analyst price target of $24.64. The stock should find initial resistance at its 50-day moving average (MA) of $18.29 and further resistance at its 200-day MA of $21.40.
Over the past year, Auxilium Pharmaceuticalshas traded in a range of $16.88 to $29.37 and are now at $16.88. The 200-day and 50-day moving averages have moved 0.09% lower and 0.74% lower over the past week, respectively.